Humanwell Pharmaceutical

What Humanwell Pharmaceutical does

Humanwell Pharmaceutical US, Inc. is a Missouri-incorporated, privately-held pharmaceutical R&D company founded in September 2015 as an independent US subsidiary of Yichang Humanwell Pharmaceutical Co. LTD. Headquartered at 421 Sovereign Court, Ballwin, MO with 11-50 US employees (and access to a parent workforce of 4,000+ globally), the company develops novel therapeutics in pain management, CNS disorders, autoimmune disease, and oncology, building on its parent company's leadership position in anesthetic and analgesic medications. The technical stack combines AI/ML-augmented computational simulation (molecular dynamics, quantum mechanics, generative AI), an AI-assisted medicinal chemistry platform with computer-aided drug design and high-throughput screening, and a portfolio of proprietary drug delivery platforms including long-acting injectables, nanoparticle formulations, gastro-retentive tablets, geomatrix multi-layer matrix tablets, and bioavailability enhancement technologies. A pilot plant supports solid-dosage manufacturing for mini-tablets, capsules, oral suspensions, and nasal sprays.

The pipeline spans New Chemical Entities (NCE), 505(b)(2) candidates, and complex generics. The lead program is RFUS-250, a small-molecule analgesic binding all three opioid receptors (KOR, DOR, MOR), which received FDA IND clearance in February 2025 and is planned to enter Phase 1 in H2 2025 for acute, chronic, neuropathic pain, and pruritus indications. Execution milestones include a first ANDA filing (Q4 2020), first ANDA approval (Q3 2022), first NDA project approval (Q1 2023), and second ANDA approval (Q3 2023).

Revenue mechanics are not publicly disclosed and are described through three streams: (1) licensing/royalty income from the development and eventual commercialization of NCE, 505(b)(2), and complex generic products; (2) professional services and end-to-end development partnerships performed at the Missouri labs; and (3) licensing/royalty income from in-licensing branded and specialty assets into the parent company's Chinese hospital and critical care channels, where Yichang Humanwell is a market leader. Go-to-market is sales-led and BD-driven, with a dedicated partnership hotline (636-220-3636) and email channel ([email protected]), targeting hospital systems, IDNs, and procurement decision-makers in anesthesia, analgesia, ICU, and critical care settings; distribution is through pharmaceutical wholesalers and the parent's network spanning 20+ countries. Pricing is not publicly disclosed.

Name

Humanwell Pharmaceutical

Legal name

Humanwell Pharmaceutical US, Inc.

Website

https://humanwellus.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Humanwell Pharmaceutical US, Inc. is a Missouri-based, privately-held pharmaceutical R&D subsidiary of Yichang Humanwell Pharmaceutical Co. LTD, developing NCE, 505(b)(2), and complex generic therapeutics in pain, CNS, autoimmune, and oncology using proprietary drug-delivery platforms and AI-assisted computational drug discovery, with lead asset RFUS-250 entering Phase 1 in 2025.

Ownership category

akta.pro rank

Product category

Pharmaceutical Research & Development

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Novel therapeutics development
• Pharmaceutical R&D services
• Drug delivery platforms
• Anesthesia and analgesia
• Complex generic formulations

Headquarters

HQ city

Ballwin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical Product Development: Development and commercialization of novel therapeutics including NCE, 505(b)(2), and complex generic products in pain, CNS, autoimmune, and oncology. Revenue generated through eventual product sales and licensing.
2. Development Partnerships: End-to-end drug development services provided to partners through state-of-the-art labs and talented team in Missouri. Also includes in-licensing opportunities for branded and specialty assets in hospital and critical care channels.
3. In-licensing Opportunities: Yichang Humanwell serves as a leader in Chinese hospital medicine market, providing access to vast and growing market for partners with branded and specialty assets in hospital and critical care channels.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Humanwell Pharmaceutical US is a pharmaceutical R&D company that discovers and develops novel therapeutics, including NCE, 505(b)(2), and complex generic products, across pain, CNS, autoimmune, and oncology indications. The company leverages proprietary drug delivery platforms (long-acting injectables, nanoparticles, gastro-retentive tablets, geomatrix tablets, bioavailability enhancement), AI-integrated computational simulation, and medicinal chemistry capabilities, alongside a solid-dosage pilot plant supporting formulation development. Lead candidate RFUS-250, a multi-opioid receptor analgesic, received FDA IND clearance in February 2025 for Phase 1 clinical trials.

Product overview

Humanwell Pharmaceutical US is a pharmaceutical R&D company developing novel therapeutics in pain, CNS, autoimmune, and oncology. The company operates a portfolio of drug delivery technology platforms (long-acting injectables, nanoparticles, gastro-retentive tablets, geomatrix tablets, bioavailability enhancement) supporting their pipeline of NCE, 505(b)(2), and complex generic products. Their lead candidate RFUS-250 is a novel analgesic currently in Phase 1 clinical trials. The company also maintains solid dosage manufacturing capabilities for mini-tablets, capsules, oral suspensions, and nasal sprays.

Differentiator

Problem solved

Functional benefit

Products and services

• RFUS-250 A novel small molecule analgesic with a unique pharmacodynamic profile that binds to all three opioid receptors (KOR, DOR, MOR); being developed for acute pain, chronic pain, neuropathic pain, and pruritus. The candidate demonstrated approximately 100x the potency of morphine in rat formalin and incision pain models with no respiratory depression, minimal constipation, low addiction potential, and no sedation at therapeutic doses, and entered Phase 1 clinical trials following FDA IND clearance.
• Pain, CNS, Autoimmune, and Oncology Development Pipeline An emerging portfolio of NCE, 505(b)(2), and complex generic drug candidates targeting therapeutic areas including hospital and ambulatory care, ICU and critical care, CNS disorders, and oncology, designed to address unmet medical needs through Humanwell's proprietary drug delivery platforms.
• End-to-End Pharmaceutical Development Partnership Services End-to-end drug development services offered from Humanwell's Missouri labs, providing partners access to AI-integrated computational simulation, medicinal chemistry, formulation development, and solid-dosage manufacturing capabilities for co-development and contract R&D engagements.
• China Hospital Medicine In-Licensing Program In-licensing program offering branded and specialty pharmaceutical asset owners access to the Chinese hospital medicine market through parent company Yichang Humanwell's established distribution and regulatory infrastructure across hospital and critical care channels.

Quantifiable outcome

• RFUS-250 showed approximately 100 times more potent efficacy than morphine in rat formalin and incision pain models
• +2 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature8 records

Partnerships

One partnership is on record.

• Yichang Humanwell Pharmaceutical Co. LTDcoreStrategic or Co-development PartnerYichang Humanwell Pharmaceutical Co. LTD is the parent company and global market leader in anesthetic and pain medications. Humanwell US is an independent subsidiary. The parent company has over 4,000 employees and delivers products to over 20 countries. Yichang Humanwell provides strategic access to the Chinese hospital medicine market and in-licensing opportunities for branded and specialty assets.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Others

• Schrödinger, Inc. Computational drug discovery platform leveraging physics-based modeling and ML; comparable on the AI/ML-driven R&D layer that Humanwell has built into its medicinal chemistry pipeline.

Broad incumbents

• Mallinckrodt Pharmaceuticals: Large specialty pharma with deep franchise in pain, CNS, and hospital injectable generics; multiple Humanwell leaders (Jun Yang, Subo Liao) previously worked there, indicating a comparable R&D and commercial scope.
• Pfizer: Global big-pharma with established pain/CNS franchises and proven AI-augmented discovery engines; VP Subo Liao is a former Pfizer Principal Scientist, and Pfizer is a relevant comparator for the AI plus medicinal chemistry approach.
• Vertex Pharmaceuticals: Large biotech with a growing non-opioid acute pain portfolio (e.g., NaV1.8 inhibitors); competing for the same hospital-based pain market and investor mindshare that Humanwell targets with RFUS-250.
• Teva Pharmaceutical Industries: World's largest generic drugmaker with substantial pain/CNS specialty pipeline and complex-generic experience; directly comparable to Humanwell's 505(b)(2) and complex generic strategy.

Direct peers

• Cara Therapeutics: Clinical-stage biotech developing selective KOR agonists for pruritus and pain; directly comparable to Humanwell's RFUS-250 (multi-opioid receptor modulator) in target indication and modality.
• Trevena Inc: Specialty pharma focused on novel CNS-acting analgesics including opioid receptor modulators; directly competes with Humanwell's pipeline in differentiated opioid pharmacology for pain.
• Collegium Pharmaceutical: Specialty pharma commercializing abuse-deterrent and pain products in the hospital and ambulatory channel; overlaps with Humanwell's target sales motion to hospital procurement and pain specialists.
• AcelRx Pharmaceuticals: Specialty pharma developing sublingual and novel-delivery analgesics for acute and post-operative pain; comparable delivery-platform-based approach and hospital-channel focus.

Emerging players

• Recursion Pharmaceuticals: AI-first biotech using ML-driven phenotypic screening for small-molecule discovery; comparable emerging AI drug discovery operator that could outpace Humanwell's internal computational platform over time.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/humanwell-pharmaceutical-us-inc./?originalSubdomain=cn

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Humanwell Pharmaceutical